Skip to content
Menu

Reported Sunday, Alpha Tau’s Alpha DaRT Achieves 100% Feasibility In 8 Recurrent Glioblastoma Patients, With Five Complete Responses And One Partial Response Among Six Evaluable Patients And No Unanticipated Serious Adverse Events

Benzinga Newsdesk 12 hours ago

News

- All eight treated brain cancer patients in the trial remain alive as of November 11, 2026; median overall survival has not been reached, with a median follow-up of 6.9 months from trial enrollment (range 3.1 to 11.6 months) in the six patients who have reached response assessment -

- All six patients who have reached response assessment achieved a RANO objective response as their best overall response, with five patients showing complete responses (83.3%), including a previously reported stable disease, and one patient with a partial response (16.7%) with a 58% decrease in tumor measurements -

- Primary endpoints of feasibility and safety: planned Alpha DaRT sources were successfully deployed in all eight patients treated to date (100%), with no unanticipated serious adverse events (SAEs) -

- Follow-up scans in several of the patients show asymptomatic radiation necrosis, a known effect of focal radiation in previously irradiated brain tissue; whether these findings suggest necrosis or tumor recurrence is expected to become clearer with additional follow-up over the coming months -

- No definitive local recurrence observed in any treated patient -

- According to the National Brain Tumor Society, glioblastoma is one of the most complex, deadly, and treatment-resistant cancers, with an estimated average survival rate of only 8 months -

- Conference call with principal investigator and the Company to be held tomorrow, Monday, November 16, 2026, at 8:30am ET -

Read at benzinga.com